Aquestive Therapeutics, Inc. (AQST) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $4.15. It has a SharesGrow Score of 42/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is AQST = $10 (+141% upside).
Valuation: AQST trades at a trailing Price-to-Earnings (P/E) of -6.1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.03.
Financials: revenue is $45M, -0.9%/yr average growth. Net income is $84M (loss), growing at -154.6%/yr. Net profit margin is -188.1% (negative). Gross margin is 58.3% (-1 pp trend).
Balance sheet: total debt is $131M with negative equity of -$34M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 3.14 (strong liquidity). Debt-to-assets is 81.9%. Total assets: $160M.
Analyst outlook: 10 / 10 analysts rate AQST as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 72/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 46/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).
